Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing anti-cancer therapeutics using precision medicine. The company's main drug, Stenoparib, is currently in a Phase 2 clinical trial for the treatment of ovarian cancer and has shown promising results in extending overall survival for patients. The company's innovative DRP platform helps identify patients who are most likely to benefit from specific anti-cancer therapeutics, leading to a potential large market potential for ovarian cancer as well as PARP inhibitors. With a strong balance sheet and enough cash to sustain operations until 2028, the company has a positive outlook for long-term growth.

Bears say

Allarity Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of anti-cancer therapeutics for patients with high unmet medical needs. Their lead program, Stenoparib, has shown potential in treating advanced recurrent ovarian cancer, but the drug still faces significant development challenges and high risks. While Allarity has recently reported promising results and is targeting a strong market, there are concerns surrounding their balance sheet, liquidity, and potential competition. Despite these risks, the current valuation of the company presents an attractive buying opportunity with significant upside potential.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.